Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application

被引:0
|
作者
Yan Pan [1 ]
Hanqiong Zhou [2 ]
Zhenqiang Sun [1 ]
Yichen Zhu [2 ]
Zhe Zhang [3 ]
Jing Han [1 ]
Yang Liu [2 ]
Qiming Wang [1 ]
机构
[1] The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Department of Internal Medicine
[2] Henan Academy of Innovations in Medical Science,Institute of Cancer Research
[3] The First Affiliated Hospital of Zhengzhou University,Department of Colorectal Surgery
[4] The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Department of Radiation Oncology
关键词
D O I
10.1038/s41419-025-07544-w
中图分类号
学科分类号
摘要
The tumor-immune response is mobilized to suppress tumorigenesis, while the immune microenvironment and lymph node microenvironment are formed gradually during tumor progression. In fact, tumor surface antigens are not easily recognized by antigen-presenting cells. So it is hard for the immune system to kill the newly formed tumor cells effectively. In a normal immune environment, immune function is always suppressed to maintain the stability of the body, and regulatory T cells play an important role in maintaining immune suppression. However, during tumorigenesis, the suppression of regulatory T cell immune functions is more likely to contribute to tumor cell proliferation and migration leading directly to tumor progression. Therefore, focusing on the role of regulatory T cells in tumor immunity could improve tumor immunotherapy outcomes in the clinic. Regulatory T cells are more mature in hematologic system tumors than in solid tumors. However, there are continuing efforts to apply regulatory T cells for immunotherapy in solid tumors. This review describes the role of regulatory T cells in solid tumor immunotherapy from the perspective of prognosis, immune microenvironment remodeling, and current clinical applications. This summary could help us better understand the mechanisms of regulatory T cells in solid tumor immunotherapy and further expand their clinical application.
引用
收藏
相关论文
共 50 条
  • [1] Targeting regulatory T cells in tumor immunotherapy
    Smyth, Mark J.
    Ngiow, Shin Foong
    Teng, Michele W. L.
    IMMUNOLOGY AND CELL BIOLOGY, 2014, 92 (06): : 473 - 474
  • [2] Regulatory T Cells and Their Clinical Applications in Antitumor Immunotherapy
    Xie, Feng
    Liang, Rui
    Li, Dan
    Li, Bin
    ENGINEERING, 2019, 5 (01) : 132 - 139
  • [3] TCR engineered T cells for solid tumor immunotherapy
    Yikai Zhang
    Zhipeng Liu
    Wei Wei
    Yangqiu Li
    Experimental Hematology & Oncology, 11
  • [4] TCR engineered T cells for solid tumor immunotherapy
    Zhang, Yikai
    Liu, Zhipeng
    Wei, Wei
    Li, Yangqiu
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [5] Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy
    Kim, Jung-Ho
    Kim, Beom Seok
    Lee, Sang-Kyou
    IMMUNE NETWORK, 2020, 20 (01)
  • [6] Tumor Infiltrating Regulatory T Cells: Tractable Targets for Immunotherapy
    Khan, Adnan R.
    Dovedi, Simon J.
    Wilkinson, Robert W.
    Pritchard, David I.
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2010, 29 (05) : 461 - 484
  • [7] Regulatory T cells: first steps of clinical application in solid organ transplantation
    van der Net, Jeroen B.
    Bushell, Andrew
    Wood, Kathryn J.
    Harden, Paul N.
    TRANSPLANT INTERNATIONAL, 2016, 29 (01) : 3 - 11
  • [8] Biological characteristics of γδT cells and application in tumor immunotherapy
    Zhu, Renhong
    Yan, Qian
    Wang, Yashu
    Wang, Keqiang
    FRONTIERS IN GENETICS, 2023, 13
  • [9] Regulatory T cells as immunotherapy
    Singer, Benjamin D.
    King, Landon S.
    D'Alessio, Franco R.
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [10] Subcutaneous and sublingual immunotherapy and T regulatory cells: there is clinical relevance
    Ciprandi, G.
    Morandi, F.
    Olcese, R.
    Silvestri, M.
    Tosca, M. A.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2010, 40 (10): : 1578 - 1579